{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:20:04Z","timestamp":1782570004973,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd010631","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T00:00:00Z","timestamp":1459814400000}}],"reference-count":227,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010631.pub2","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T16:37:38Z","timestamp":1459874258000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chlorpromazine versus atypical antipsychotic drugs for schizophrenia"],"prefix":"10.1002","volume":"2016","author":[{"given":"Kumar B","family":"Saha","sequence":"first","affiliation":[{"name":"Leeds and York Partnerships NHS Foundation Trust; Addiction Psychiatry; Leeds Addiction Unit 19 Springfield Mount Leeds UK LS2 9NG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Bo","sequence":"additional","affiliation":[{"name":"Xiyuan Hospital; China Academy of Chinese Medical Sciences; 1 Xi Yuan Cao Chang Haidian District Beijing China 100091"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Systematic Review Solutions Ltd; 5-6 West Tashan Road Yan Tai Tianjin China 264000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health University of Nottingham Innovation Park, Triumph Road, Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sampson","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Institute of Mental Health University of Nottingham Innovation Park, Jubilee Campus Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid U","family":"Zaman","sequence":"additional","affiliation":[{"name":"Oxford Policy Management; Health Portfolio; 6 St Aldates Courtyard 38 St Aldates Oxford Oxfordshire UK OX1 1BN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,5]]},"reference":[{"issue":"Supplement 3","key":"10.1002\/14651858.CD010631.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/S0924-977X(00)80401-0","article-title":"Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine","volume":"10","author":"Dossenbach","year":"2000","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0002|cit2","unstructured":"Eli Lilly Company Study F1D-VI-HGCQ olanzapine versus chlorpromazine in Turkey Unpublished document internal to Eli-Lilly 2000 1 560"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD010631.pub2-BIB0003|cit3","first-page":"S369","article-title":"Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]","volume":"11","author":"Kostakoglu","year":"2001","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Mraz K Gogus A Tunca Z Martenyi F Dossenbach M Olanzapine versus chlorpromazine in Turkey Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5-11, 2000; Davos, Switzerland) 2000","DOI":"10.1016\/S0920-9964(00)90764-3"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0005|cit5","unstructured":"Eli Lilly Company Study HGDV olanzapine (versus chlorpromazine in Morocco) Unpublished document internal to Eli-Lilly and Company 2001 1 512"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0006|cit6","unstructured":"HGDV\/Morocco Data supplied to the Cochrane Schizophrenia Group Data on file 1999"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0007|cit7","first-page":"144","article-title":"Olanzapine on effect of executive dysfunction in schizophrenia","volume":"16","author":"An","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010631.pub2-BIB0008|cit8","first-page":"357","article-title":"Clinical effects of olanzapine vs chlorpromazine in treating positive symptoms of schizophrenia","volume":"22","author":"Chang","year":"2003","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0009|cit9","first-page":"303","article-title":"Olanzapine and chlorpromazine in the treatment of schizophrenia","volume":"16","author":"Chen","year":"2006","journal-title":"Journal of Clinical Psychiatric Medicine"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0010|cit10","first-page":"78","article-title":"A comparative trial of olanzapine versus chlorpromazine in the treatment of schizophrenia","volume":"16","author":"He","year":"2003","journal-title":"Shandong Mental Health Archive"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0011|cit11","unstructured":"Eli Lilly Company HGDT olanzapine versus chlorpromazine in Egypt Unpublished document internal to Eli Lilly and Company 2001 1 513"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD010631.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0924-977X(99)80354-X","article-title":"Olanzapine compared to chlorpromazine in acute schizophrenia","volume":"9","author":"Loza","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0013|cit13","first-page":"401","article-title":"Comparative study of the effect of olanzapine on serum lipid in schizophrenia","volume":"17","author":"Luo","year":"2007","journal-title":"Journal of Clinical Psychiatric Medicine"},{"issue":"17","key":"10.1002\/14651858.CD010631.pub2-BIB0014|cit14","first-page":"2664","article-title":"Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients","volume":"6","author":"Wang","year":"2002","journal-title":"Zhongguo lin chuang kang fu [Chinese Journal of Clinical Rehabilitation]"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0015|cit15","first-page":"373","article-title":"A comparative study of olanzapine in treatment of schizophrenia","volume":"21","author":"Wang","year":"2008","journal-title":"Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0016|cit16","first-page":"8","article-title":"Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia","volume":"21","author":"Wu","year":"2008","journal-title":"Sichuan Mental Health Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0017|cit17","first-page":"41","article-title":"A comparative study on olanzapine and chlorpromazine in the treatment of schizophrenia","volume":"14","author":"Zhao","year":"2006","journal-title":"China Journal of Health Psychology"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0018|cit18","first-page":"285","article-title":"A comparative study of efficacy and safety of seroquel versus chlorpromazine in the treatment of schizophrenia","volume":"31","author":"Ai","year":"2007","journal-title":"Heilongjiang Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0019|cit19","first-page":"62","article-title":"A comparison of intelligence disorders and memory disorders in the first-onset schizophrenia treated with quetiapine and chlorpromazine","volume":"14","author":"An","year":"2005","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0020|cit20","first-page":"281","article-title":"Clinical comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"18","author":"Cai","year":"2006","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0021|cit21","first-page":"12","article-title":"Quetiapine and chlorpromazine in the treatment of schizophrenia: a random, controlled trial","volume":"19","author":"Cai","year":"2007","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"36","key":"10.1002\/14651858.CD010631.pub2-BIB0022|cit22","first-page":"63","article-title":"Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia","volume":"9","author":"Cao","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation [Zhongguo Lin Chuang Kang Fu]"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0023|cit23","first-page":"193","article-title":"Multi-center, double blind control study of domestic manufactured quetiapine on schizophrenia","volume":"34","author":"Chen","year":"2001","journal-title":"Chinese Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0024|cit24","first-page":"149","article-title":"A double-blind and double-dummy comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"11","author":"Zhao","year":"2002","journal-title":"Chinese New Drugs Journal"},{"issue":"5","key":"10.1002\/14651858.CD010631.pub2-BIB0025|cit25","first-page":"319","article-title":"Quetiapine treatment in schizophrenia curative effect and quality of life","volume":"17","author":"Chen","year":"2007","journal-title":"Journal of Clinical Psychiatry [Linchuang Jingshen Yixue Zazhi]"},{"issue":"7","key":"10.1002\/14651858.CD010631.pub2-BIB0026|cit26","first-page":"660","article-title":"Quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"20","author":"Chen","year":"2008","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0027|cit27","first-page":"78","article-title":"Control observation of quetiapine vs chlorpromazine in schizophrenia","volume":"9","author":"Cheng","year":"2003","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0028|cit28","first-page":"496","article-title":"\u5229\u57f9\u916e\u5408\u7528\u6c2f\u785d\u897f\u6cee\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u6025\u6027\u671f\u5174\u594b\u72b6\u6001\u7597\u6548\u89c2\u5bdf","volume":"24","author":"Deng","year":"2004","journal-title":"\u4e2d\u56fd\u5b9e\u7528\u5185\u79d1\u6742\u5fd7"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0029|cit29","first-page":"75","article-title":"Control studies on efficacy of quetiapine vs chlorpromazine in first - episode schizophrenics","volume":"9","author":"Guo","year":"2003","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD010631.pub2-BIB0030|cit30","first-page":"454","article-title":"A comparative study on the effects of quetiapine and chlorpromazine upon the life quality of patients with schizophrenia","volume":"3","author":"Guo","year":"2003","journal-title":"Nervous Diseases and Mental Hygiene"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0031|cit31","first-page":"443","article-title":"Domestic quetiapine and chlorpromazine in the treatment of schizophrenia in controlled clinical studies","volume":"14","author":"Guo","year":"2005","journal-title":"Modern Journal of Integrated Traditional Chinese and Western Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010631.pub2-BIB0032|cit32","first-page":"257","article-title":"The effect of chlorpromazine and quetiapine on serum lipid and glucose","volume":"16","author":"Guo","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD010631.pub2-BIB0033|cit33","first-page":"583","article-title":"Effect of quetiapine and chlorpromazine on cognitive function in first-episode schizophrenic","volume":"15","author":"Guo","year":"2007","journal-title":"Chinese Journal of Health Psychology"},{"issue":"5","key":"10.1002\/14651858.CD010631.pub2-BIB0034|cit34","first-page":"544","article-title":"Efficacy quetiapine in the treatment of schizophrenic patients and effect on the quality of life","volume":"16","author":"Guo","year":"2008","journal-title":"Chinese Journal of Health Psychology"},{"issue":"10","key":"10.1002\/14651858.CD010631.pub2-BIB0035|cit35","first-page":"680","article-title":"A comparative study of quetiapine and chlorpromazine in the treatment of patients with schizophrenia","volume":"22","author":"He","year":"2003","journal-title":"Herald of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010631.pub2-BIB0036|cit36","first-page":"467","article-title":"The effects of antipsychotics on serum prolactin in the first-episode schizophrenia patients","volume":"18","author":"Hu","year":"2003","journal-title":"West China Journal of Pharmaceutical Sciences"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0037|cit37","first-page":"73","article-title":"Comparative study between the quality of life and its curative effect in schizophrenic patients treated with quetiapine or chlorpromazine","volume":"17","author":"Ji","year":"2004","journal-title":"Sichuan Mental Health"},{"issue":"6","key":"10.1002\/14651858.CD010631.pub2-BIB0038|cit38","first-page":"352","article-title":"A random and controlled study of quetiapine and chlorpromazine in patients with schizophrenia","volume":"16","author":"Jiang","year":"2006","journal-title":"Journal of Clinical Psychiatry [Linchuang Jingshen Yixue Zazhi]"},{"issue":"16","key":"10.1002\/14651858.CD010631.pub2-BIB0039|cit39","first-page":"1835","article-title":"A controlled study of quetiapine and chlorpromazine for schizophrenia","volume":"37","author":"Jiang","year":"2008","journal-title":"Chongqing Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD010631.pub2-BIB0040|cit40","first-page":"56","article-title":"Seroquel and chlorpromazine in treatment of schizophrenia: a random, controlled trial","volume":"16","author":"Jin","year":"2007","journal-title":"China Pharmaceuticals"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0041|cit41","first-page":"200","article-title":"Effects of quetiapine and chlorpromazine on serum prolactin of schizophrenics","volume":"9","author":"Kong","year":"2003","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0042|cit42","first-page":"135","article-title":"A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia","volume":"16","author":"Li","year":"2003","journal-title":"Shandong Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0043|cit43","first-page":"395","article-title":"Quetiapine and chlorpromazine in the treatment of schizophrenia with depression","volume":"31","author":"Li","year":"2010","journal-title":"Journal of Qiqi ha-er Medical College"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0044|cit44","first-page":"164","article-title":"Quetiapine for late onset schizophrenia","volume":"16","author":"Liu","year":"2003","journal-title":"Shandong Archive of Psychiatry"},{"issue":"17","key":"10.1002\/14651858.CD010631.pub2-BIB0045|cit45","first-page":"723","article-title":"Comparison of efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"19","author":"Mei","year":"2007","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0046|cit46","first-page":"38","article-title":"Effect of quetiapine on cognition function of patients with first episode schizophrenia","volume":"28","author":"Nai","year":"2007","journal-title":"Journal of Medical Forum"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0047|cit47","unstructured":"NCT00882518 Efficacy and safety of quetiapine fumarate in the treatment of schizophrenic patients http:\/\/www.clinicaltrials.gov"},{"issue":"6","key":"10.1002\/14651858.CD010631.pub2-BIB0048|cit48","first-page":"606","article-title":"A randomized double - blind controlled study on the efficacy of quetiapine and chlorpromazine in treatment of schizophrenia","volume":"21","author":"Peng","year":"2006","journal-title":"West China Journal of Pharmaceutical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1997.tb10162.x","article-title":"A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"96","author":"Peuskens","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0050|cit50","first-page":"94","article-title":"Effect of cognitive function in first-episode schizophrenia treated with quetiapine","volume":"16","author":"Sun","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD010631.pub2-BIB0051|cit51","first-page":"682","article-title":"Comparative study on the effect of seroquel and chlorpromazine on schizophrenia","volume":"17","author":"Tian","year":"2006","journal-title":"China Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0052|cit52","first-page":"55","article-title":"A double blind controlled study of quetiapine and chlorpromazine for schizophrenia","volume":"24","author":"Wan","year":"2002","journal-title":"Journal of Yichun University"},{"issue":"11","key":"10.1002\/14651858.CD010631.pub2-BIB0053|cit53","first-page":"1151","article-title":"A controlled study of quetiapine and chlorpromazine for schizophrenia","volume":"20","author":"Wan","year":"2008","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0054|cit54","first-page":"288","article-title":"Comparison of efficacy and safety of quetiapine and larctigal in the treatment of schizophrenia","volume":"13","author":"Wang","year":"2004","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0055|cit55","first-page":"83","article-title":"Efficacy of quetiapine in the treatment of female patients with schizophrenia","volume":"17","author":"Wang","year":"2005","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD010631.pub2-BIB0056|cit56","first-page":"1050","article-title":"Quetiapine and chlorpromazine in the treatment of people with schizophrenia","volume":"19","author":"Yang","year":"2007","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0057|cit57","first-page":"149","article-title":"A double-blind study of domestic quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"15","author":"Zhang","year":"2002","journal-title":"Shandong Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0058|cit58","first-page":"163","article-title":"A comparison study on efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"19","author":"Zhang","year":"2003","journal-title":"Chinese Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0059|cit59","unstructured":"Ma J Quetiapine and chlorpromazine in the treatment of first-episode schizophrenia controlled clinical studies Chinese Clinical Practical Medicine 2007 51 2"},{"issue":"9","key":"10.1002\/14651858.CD010631.pub2-BIB0060|cit60","first-page":"1038","article-title":"Quetiapine and chlorpromazine in the treatment of first-episode schizophrenia controlled clinical studies","volume":"28","author":"Ma","year":"2007","journal-title":"Journal of Qiqihar Medical College [Qiqihar Yixueyuan Xuebao]"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0061|cit61","first-page":"81","article-title":"Comparison study on treatment of primary schizophrenia with quetiapine and chlorpromazine","volume":"30","author":"Zhang","year":"2006","journal-title":"Heilongjiang Nursing Journal [Modern Nursing]"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0062|cit62","first-page":"149","article-title":"A controlled study of quetiapine and chlorpromazine for schizophrenia","volume":"8","author":"Zhang","year":"2008","journal-title":"Neurological Disorders and Mental Health"},{"issue":"10","key":"10.1002\/14651858.CD010631.pub2-BIB0063|cit63","first-page":"699","article-title":"Comparison between quetiapine and chlorpromazine in cognitive function of schizophrenic patients","volume":"17","author":"Zhou","year":"2003","journal-title":"Chinese Mental Health Journal"},{"issue":"11","key":"10.1002\/14651858.CD010631.pub2-BIB0064|cit64","first-page":"657","article-title":"A comparative study on quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"16","author":"Zhou","year":"2004","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"12","key":"10.1002\/14651858.CD010631.pub2-BIB0065|cit65","first-page":"51","article-title":"Study on quetiapine and chlorpromazine in treatment of schizophrenia","volume":"15","author":"Zou","year":"2006","journal-title":"China Pharmaceuticals"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0066|cit66","unstructured":"Chang SL Wang GH Clinical observation of risperidone and chlorpromazine in the treatment of schizophrenia Anhui Medical and Pharmaceutical Journal 1998 25 6"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0067|cit67","first-page":"205","article-title":"Risperidone and chlorpromazine in the treatment of schizophrenia, double-blind, controlled study, and serum prolactin efficacy","volume":"14","author":"Cui","year":"2001","journal-title":"Hebei Archive of Psychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0068|cit68","first-page":"117","article-title":"A comparative study on the effects of risperidone and chlorpromazine upon the life quality of patients with schizophrenia","volume":"11","author":"Feng","year":"2003","journal-title":"Health Psychology Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0069|cit69","first-page":"185","article-title":"A controlled comparative study on risperidone and chlorpromazine in treatment of schizophrenia","volume":"8","author":"He","year":"1999","journal-title":"Chinese New Drugs Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0070|cit70","first-page":"27","article-title":"Risperidone and chlorpromazine in the treatment of clinical controlled study of 70 patients with schizophrenia","volume":"4","author":"Lin","year":"2005","journal-title":"Modern Chinese Practical Medicine Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0071|cit71","first-page":"323","article-title":"A comparative study of risperidone and chlorpromazine in the treatment of the negative symptoms of schizophrenia","volume":"19","author":"Liu","year":"2000","journal-title":"Journal of Medicine and Pharmacy"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0072|cit72","first-page":"443","article-title":"Risperidone and chlorpromazine on schizophrenia blood pressure, heart rate","volume":"21","author":"Liu","year":"2005","journal-title":"Occupation and Health"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0073|cit73","first-page":"264","article-title":"Comparison of effects and factors between risperidone and chlorpromazine on schizophrenia","volume":"20","author":"Luo","year":"2001","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0074|cit74","first-page":"202","article-title":"A comparative study of risperidone and chlorpromazine in the treatment of schizophrenia","volume":"16","author":"Ma","year":"2004","journal-title":"Medical Journal of Chinese People Health"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0075|cit75","first-page":"226","article-title":"Controlled study of risperidone and chlorpromazine in the treatment of schizophrenia","volume":"10","author":"Wang","year":"2002","journal-title":"Health Psychology Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0076|cit76","first-page":"342","article-title":"Effect of chlorpromazine and risperidone on cognitive function of the patients with first episode schizophrenia","volume":"13","author":"Wang","year":"2005","journal-title":"Chinese Journal of Health Psychology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0077|cit77","first-page":"364","article-title":"A comparative trial on the efficacy of risperidone vs chlorpromazine in chronic schizophrenia","volume":"10","author":"Wu","year":"2002","journal-title":"Health Psychology Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0078|cit78","first-page":"137","article-title":"A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia","volume":"17","author":"Wu","year":"2004","journal-title":"Shandong Archive of Psychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0079|cit79","first-page":"99","article-title":"Efficacy of risperidone and chlorpromazine in the treatment of schizophrenia","volume":"21","author":"Zheng","year":"2001","journal-title":"Chinese Hospital Pharmacy Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0080|cit80","unstructured":"Appelberg B Sintonen H Tuisku K Joffe G Is it worthwhile to change clinically stable schizophrenic outpatients with mild to moderate residual symptoms and\/or side effects from conventional to atypical antipsychotics? - a randomised study with olanzapine Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland 2004"},{"issue":"8","key":"10.1002\/14651858.CD010631.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eurpsy.2004.06.035","article-title":"Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and\/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine","volume":"19","author":"Appelberg","year":"2004","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0082|cit82","first-page":"140","article-title":"Is it worthwhile changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and\/or side effects from conventional to atypical antipsychotics?","volume":"67","author":"Appelberg","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1017\/S0266462308080525","article-title":"Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: a prospective, randomized study","volume":"24","author":"Joffe","year":"2008","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0086|cit84","unstructured":"Beasley CM Beuzen JN Birkett MA New Clinical Drug Evaluation Unit (NCDEU) Meeting; 1999 June 12-15; Boca Raton, FL, USA 1999"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0084|cit85","unstructured":"Beasley CM Beuzen JN Birkett MA Olanzapine versus clozapine: an international double-blind study in the treatment of patients with treatment-resistent schizophrenia American College of Neuropsychopharmacology Annual Meeting Hawaii 1998"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0085|cit86","unstructured":"Beasley CM Beuzen JN Birkett MA Olanzapine versus clozapine: an international double-blind study in the treatment of patients with treatment-resistent schizophrenia American Psychiatric Association Meeting; 1999 January 31 - February 2; Washington, DC, USA 1999"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0087|cit87","unstructured":"Beasley CM Beuzen JN Birkett MA Olanzapine versus clozapine: an international double-blind study in the treatment of patients with treatment-resistent schizophrenia World Psychiatric Association; 1999 August 6-11; Hamburg, Germany 1999"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0088|cit88","unstructured":"Beuzen JN Birkett M Kiesler G Wood A Olanzapine versus clozapine in resistant schizophrenic patients - results of an international double-blind randomised clinical trial Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; 1998 July 12-16; Glasgow, UK 1998"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010631.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/S0924-977X(98)80379-9","article-title":"An investigation of subgroup effects in a study of olanzapine versus clozapine in the treatment of resistant schizophrenic patients","volume":"8","author":"Beuzen","year":"1998","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010631.pub2-BIB0090|cit90","first-page":"S140","article-title":"Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents","volume":"3","author":"David","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0091|cit91","unstructured":"Dossenbach M Bitter I Slabber M Pretorius J Bartko GY Banics Z Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA 2000"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0092|cit92","unstructured":"Dossenbach M Bitter I Slabber M Pretorius J Bartko GY Banics Z Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0093|cit93","unstructured":"Dossenbach M Slabber M Martenyi F Bartko G Bitter I Olanzapine vs. clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999 148"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0094|cit94","unstructured":"Jean-Noel B Wood AJ Kiesler GM Birkett M Tollefson GD Olanzapine vs. clozapine: an international double blind study in the treatment of resistant schizophrenia 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999 143"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0101|cit96","first-page":"31","article-title":"A comparative longitudinal study of risperidone versus classic neuroleptic drugs in the treatment of schizophrenia: 24 months observation","volume":"28","author":"Bouchard","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0096|cit97","unstructured":"Bouchard RH Demers MF Merette E Pourcher E Classical neuroleptics (CNLP) vs risperidone (RIS) interim 12 months efficacy analysis of a long-term, naturalistic study in schizophrenia 21st Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP); 1998 Jul 12-16; Glassgow, UK 1998"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0098|cit98","unstructured":"Bouchard RH Merette C Demers MF Roy-Gagnon MH Risperidone versus classical neuroleptics: preliminary results of a prospective naturalistic one year study 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto Toronto, Canada 1998 180"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0097|cit99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00004714-200006000-00002","article-title":"Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group","volume":"20","author":"Bouchard","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0099|cit100","doi-asserted-by":"crossref","unstructured":"Bouchard RH Pourcher E Merette C Demers MF Villeneuve J Roy Gagnon MH One-year follow-up of schizophrenic patients treated with risperidone or classical neuroleptics: a prospective, randomized, multicentred open-study 11th Congress of the European College of Neuropsychoharmacology; 1998 Oct 31- Nov 4; Paris, France 1998","DOI":"10.1016\/S0924-977X(98)80455-0"},{"issue":"1-3","key":"10.1002\/14651858.CD010631.pub2-BIB0100|cit101","first-page":"271","article-title":"Risperidone advantages in chronic schizophrenic patients: a 1-year effectiveness study","volume":"36","author":"Bouchard","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0102|cit102","first-page":"325","article-title":"Clinical observation on schizophrenic patients treated with risperidone","volume":"11","author":"Chen","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0103|cit103","doi-asserted-by":"crossref","unstructured":"Conley R Gounaris C Demographic differences in olanzapine responders with therapy-refractory schizophrenia Schizophrenia Research the VIth International Congress on Schizophrenia Research;1997 April 12-16; Colorado Springs, CO 1997 189","DOI":"10.1016\/S0920-9964(97)82542-X"},{"issue":"7","key":"10.1002\/14651858.CD010631.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1176\/ajp.155.7.914","article-title":"Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia","volume":"155","author":"Conley","year":"1998","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0105|cit105","doi-asserted-by":"crossref","unstructured":"Conley RR Tamminga CA Beasley C Olanzapine vs chlorpromazine in therapy-refractory schizophrenia Schizophrenia Research, The VIth International Congress on Schizophrenia Research; 1997 April 12-16; Colorado Springs, CO 1997 189","DOI":"10.1016\/S0920-9964(97)82542-X"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0106|cit106","first-page":"1S","article-title":"Olanzapine vs. chlorpromazine in treatment-resistant schizophrenia","volume":"41","author":"Conley","year":"1997","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0107|cit107","first-page":"73S","article-title":"Olanzapine vs. chlorpromazine in treatment-resistant schizophrenia","volume":"41","author":"Conley","year":"1997","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0920-9964(99)00053-5","article-title":"Differential olanzapine plasma concentrations by sex in a fixed-dose study","volume":"40","author":"Kelly","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Richardson C Conley R Olanzapine response in schizophrenic subjects with neuroleptic resistant disorganization Schizophrenia Research, The VIth International Congress on Schizophrenia Research; 1997 April 12-16; Colorado Springs, CO 1997 191","DOI":"10.1016\/S0920-9964(97)82546-7"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4088\/JCP.v62n0310","article-title":"Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis","volume":"62","author":"Czekalla","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010631.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00406-004-0514-1","article-title":"The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders","volume":"254","author":"Jesus Mari","year":"2004","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010631.pub2-BIB0112|cit112","first-page":"S140","article-title":"Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents","volume":"3","author":"David","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0113|cit113","unstructured":"Edgell ET Andersen SW Grainger D Wang J Resource use and quality of life of olanzapine compared with risperidone: results from an international randomized clinical trial XXIst Collegium Internationale Neuro-psychopharmacologicum; 1998, July 12-16; Glasgow, UK 1998"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0114|cit114","first-page":"95","article-title":"A comparative trial on the efficacy of risperidone vs chlorpromazine in treatment-resistant schizophrenia","volume":"14","author":"Feng","year":"2001","journal-title":"Shandong Archive of Psychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0115|cit115","first-page":"428","article-title":"Comparative analysis of the positive symptoms of schizophrenia treated with risperidone","volume":"14","author":"Hu","year":"2005","journal-title":"Chinese Journal of Behavioral Medical Science"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0116|cit116","first-page":"396","article-title":"Risperidone vs chlorpromazine in treating schizophrenia: a randomized double-blind study","volume":"19","author":"Huang","year":"2000","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0117|cit117","first-page":"210","article-title":"Risperidone and chlorpromazine, clozapine drug-control study","volume":"8","author":"Huang","year":"2000","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0118|cit118","first-page":"S369","article-title":"Olanzapine vs. chlorpromazine- 6 weeks treatment of acute schizophrenia","volume":"11","author":"Kostakoglu","year":"2001","journal-title":"Journal of European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0119|cit119","first-page":"18","article-title":"Initial searching for the early influence and interfere about the regulating function of the blood-glucose affected by chlorpromazine and risperidal","volume":"4","author":"Li","year":"2007","journal-title":"Journal of Health and Well Being"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/S0924-977X(97)88676-2","article-title":"Risperidone in the treatment of acute schizophrenic episodes","volume":"7","author":"Pappas","year":"1997","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0121|cit121","first-page":"68","article-title":"Metabolism of the blood-glucose that affected by chlorpromazine or risperidone treatment","volume":"16","author":"Qu","year":"2006","journal-title":"Journal of Clinical Psychiatric Medicine [Linchuang Jingshen Yixue Zazhi]"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0122|cit122","first-page":"487","article-title":"Effects of risperidone on NEF of eye movements in the first-episode schizophrenia","volume":"13","author":"Shi","year":"2007","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0123|cit123","first-page":"380","article-title":"Effects of low dosage risperdal to treat the first attack of schizophrenia","volume":"30","author":"Su","year":"2002","journal-title":"Youjiang Medical Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0124|cit124","first-page":"151","article-title":"Risperidone combined with chlorpromazine in the treatment of insomnia clinical observation of patients with schizophrenia","volume":"11","author":"Tian","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0924-977X(96)87987-9","article-title":"An atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study","volume":"6","author":"Arvanitis","year":"1996","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0126|cit126","unstructured":"AstraZeneca A multicentre, double-blind, randomised trial to compare the effects of seroquel and chlorpromazine in patients with treatment-resistant schizophrenia (5077IL\/0054 TRESS) http:\/\/www.clinicalstudyresults.org\/"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0127|cit127","unstructured":"AstraZeneca A multicenter, double-blind, randomized, comparison of quetiapine (seroquel\u00ae) and chlorpromazine in the treatment of subjects with treatment-resistant schizophrenia http:\/\/www.clinicalstudyresults.org\/"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0128|cit128","first-page":"1028","article-title":"Quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"18","author":"Bai","year":"2006","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"21","key":"10.1002\/14651858.CD010631.pub2-BIB0129|cit129","first-page":"52","article-title":"Clinical effects comparison of quetiapine and chlorpromazine hydrochloride in treatment of female schizophrenia","volume":"17","author":"Cai","year":"2008","journal-title":"China Pharmaceuticals"},{"issue":"7","key":"10.1002\/14651858.CD010631.pub2-BIB0130|cit130","first-page":"398","article-title":"A clinical comparative analysis of quetiapine and chlorpromazine in treatment of schizophrenia","volume":"16","author":"Du","year":"2004","journal-title":"Medical Journal of Chinese People's Health"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0131|cit131","unstructured":"Jiang K Quetiapine vs chlorpromazine for schizophrenia - a multi-centre, randomized controlled clinical trial Proceedings of the 1st Chinese National Conference of Psycho-Neuroscience; 2004 Unknown Dates; Changsha, China Changsha, China 2004 106"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0132|cit132","first-page":"26","article-title":"Comparative analysis of side effects of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"6","author":"Li","year":"2005","journal-title":"Practical Clinical Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010631.pub2-BIB0133|cit133","first-page":"273","article-title":"Quetiapine (35 patients) vs chlorpromazine (34 patients) in treatment of schizophrenia","volume":"23","author":"Ma","year":"2004","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0134|cit134","first-page":"138","article-title":"A comparison of cognitive function in first episode schizophrenia treated with seroquel or chlorpromazine","volume":"16","author":"Ning","year":"2008","journal-title":"Chinese Journal of Health Psychology"},{"issue":"11","key":"10.1002\/14651858.CD010631.pub2-BIB0135|cit135","first-page":"14","article-title":"Quetiapine and chlorpromazine in the treatment of schizophrenia observed","volume":"3","author":"Tang","year":"2004","journal-title":"Chinese Modern Medicine"},{"issue":"9","key":"10.1002\/14651858.CD010631.pub2-BIB0136|cit136","first-page":"917","article-title":"Comparison of efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"20","author":"Tang","year":"2008","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0137|cit137","first-page":"255","article-title":"A comparative study of effects of quetiapine and chlorpromazine on the brain blood stream dynamics in the treatment of schizophrenia","volume":"17","author":"Wang","year":"2007","journal-title":"Linchuang Jingshen Yixue Zazhi"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0138|cit138","first-page":"97","article-title":"A comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"9","author":"Zhang","year":"2007","journal-title":"Chinese Modern Medicine and Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0139|cit139","first-page":"103","article-title":"Comparative study of influence of quetiapine on life quality in schizophrenic patients","volume":"15","author":"Zhong","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0140|cit140","first-page":"57","article-title":"Random comparing research on the treatment of schizophrenia by risperidone and chlorpromazine","volume":"10","author":"Wang","year":"1998","journal-title":"Tianjin Pharmacy"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0141|cit141","first-page":"203","article-title":"A comparative trial of the efficacy on olanzapine and chlorpromazine in treatment-resistant schizophrenia","volume":"12","author":"Wang","year":"2004","journal-title":"Heath Psychology Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0142|cit142","first-page":"1417","article-title":"Study on influence of the short - term therapy by chlorpromazine or risperidal on 2hPG","volume":"27","author":"Wang","year":"2006","journal-title":"Journal of Qiqihar Medical College [Qiqihar Yixueyuan Xuebao]"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0143|cit143","first-page":"697","article-title":"Comparison study of childhood schizophrenia treated with risperidone and chlorpromazine","volume":"28","author":"Xiong","year":"2004","journal-title":"Guizhou Medical Journal"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0144|cit144","first-page":"265","article-title":"A comparison of cognitive function in schizophrenia treated with risperidone and chlorpromazine","volume":"11","author":"Yu","year":"2001","journal-title":"Journal of Clinical Psychological Medicine"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0145|cit145","first-page":"197","article-title":"The first use of chlorpromazine and risperidone on glucose metabolism in patients with schizophrenia","volume":"19","author":"Yuan","year":"2006","journal-title":"Sichuan Mental Health"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0146|cit146","first-page":"153","article-title":"A comparative trial on the efficacy of risperidone vs chlorpromazine in the treatment of chronic schizophrenia","volume":"17","author":"Zou","year":"2005","journal-title":"Medical Journal of Chinese People's Health"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1741-7015-3-15","article-title":"Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials","volume":"3","author":"Adams","year":"2005","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1192\/bjp.bp.106.029983","article-title":"The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries","volume":"189","author":"Adams","year":"2006","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0149|cit149","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000284.pub3","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007445.pub2","article-title":"Chlorpromazine for psychosis induced aggression or agitation","author":"Ahmed","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0151|cit151","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006329","article-title":"Cessation of medication for people with schizophrenia already stable on chlorpromazine","author":"Almerie","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD010631.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD010631.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia. Definition and reliability","volume":"39","author":"Andreasen","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0154|cit154","volume-title":"Scale for the Assessment of Positive Symptoms (SANS)","author":"Andreasen","year":"1984"},{"issue":"9709","key":"10.1002\/14651858.CD010631.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0140-6736(10)60030-X","article-title":"Scientific fraud: action needed in China","volume":"375","author":"Anon","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD010631.pub2-BIB0156|cit156","first-page":"5","article-title":"An overview of side effects caused by typical antipsychotics","volume":"61","author":"Arana","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pnpbp.2007.06.031","article-title":"The effect of atypical antipsychotic drugs, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma","volume":"32","author":"Bian","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/archpsyc.1978.01770250074007","article-title":"Prognosis in schizophrenia. Prognostic predictors and outcome","volume":"35","author":"Bland","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"7108","key":"10.1002\/14651858.CD010631.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0160|cit160","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0161|cit161","first-page":"33-48","article-title":"New atypical antipsychotic drugs for schizophrenia: iloperidone","volume":"4","author":"Caccia","year":"2010","journal-title":"Drug Design, Development and Therapy"},{"issue":"2-3","key":"10.1002\/14651858.CD010631.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000065140","article-title":"Chinese classification of mental disorders (CCMD-3): towards integration in international classification","volume":"35","author":"Chen","year":"2002","journal-title":"Psychopathology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0163|cit163","first-page":"233","article-title":"Extrapyramidal Symptom Rating Scale (abstract)","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurogical Sciences"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0164|cit164","first-page":"429","article-title":"Emerging role of sertindole in the management of schizophrenia","volume":"7","author":"Cincotta","year":"2010","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0165|cit165","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0166|cit166","unstructured":"Deeks JJ Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0167|cit167","first-page":"479","article-title":"The treatment of psychosis in a derivative of the neuroleptic hibernotherapie method","volume-title":"CR Congr\u00e8s des M\u00e9dicins Ali\u00e9nistes et Neurologistes de France et des Pays de Langue Fran\u00e7aise","author":"Delay","year":"1952"},{"issue":"6","key":"10.1002\/14651858.CD010631.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD010631.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0170|cit170","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0171|cit171","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"issue":"7109","key":"10.1002\/14651858.CD010631.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0174|cit174","first-page":"56","article-title":"Measurement of the quality of life: Current state of the art","volume":"63","author":"Flanagan","year":"1982","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD010631.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0177|cit177","first-page":"124","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"7414","key":"10.1002\/14651858.CD010631.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0180|cit180","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0181|cit181","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0182|cit182","unstructured":"Higgins JPT Deeks JJ Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1097-4679(196501)21:1<65::AID-JCLP2270210122>3.0.CO;2-I","article-title":"The nurses' observation scale for inpatient evaluation: a new scale for measuring improvement in chronic schizophrenia","volume":"21","author":"Honigfeld","year":"1965","journal-title":"Journal of Clinical Psychology"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0185|cit185","first-page":"86","article-title":"F-20","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders","author":"World Health Organization","year":"1992"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0186|cit186","unstructured":"ICH Expert Working Group ICH harmonised tripartite guideline: structure and content of clinical study reports International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties","volume":"244","author":"Janssen","year":"1988","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0188|cit188","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"1-2","key":"10.1002\/14651858.CD010631.pub2-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/BF02245602","article-title":"Mechanisms of action of atypical antipsychotic drugs: a critical analysis","volume":"124","author":"Kinon","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0191|cit191","volume-title":"Dementia Praecox and Paraphrenia","author":"Kraeplin","year":"1919"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0192|cit192","first-page":"1329","article-title":"Artificial hibernation by physical and pharmacodynamic means","volume":"59","author":"Laborit","year":"1951","journal-title":"Presse M\u00e9dicale"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD010631.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotic drugs an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0196|cit196","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004278.pub2","article-title":"Haloperidol versus chlorpromazine for schizophrenia","author":"Leucht","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9657","key":"10.1002\/14651858.CD010631.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0198|cit198","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007778","article-title":"Chlorpromazine dose for people with schizophrenia","author":"Liu","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010631.pub2-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","article-title":"The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders","volume":"14","author":"Maier","year":"1988","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD010631.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3949\/ccjm.74.8.597","article-title":"Atypical antipsychotics: new drugs, new challenges","volume":"74","author":"Mathews","year":"2007","journal-title":"Cleveland Clinic Journal of Medicine"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiologic Reviews"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1007\/BF00442554","article-title":"Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia","volume":"99 Suppl","author":"Meltzer","year":"1989","journal-title":"Psychopharmacology"},{"issue":"19","key":"10.1002\/14651858.CD010631.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1523\/JNEUROSCI.21-19-07733.2001","article-title":"Wisconsin Card Sorting revisited: distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging","volume":"21","author":"Monchi","year":"2001","journal-title":"The Journal of Neuroscience"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1527-3458.2001.tb00199.x","article-title":"Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist","volume":"7","author":"Nadal","year":"2001","journal-title":"CNS Drug Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000468572","article-title":"Psychotropic drug prescription pattern in a developing country (Nigeria). The need for an essential psychotherapeutic drug list","volume":"17","author":"Odejide","year":"1982","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00434408","article-title":"The Leeds Sleep Evaluation Questionnaire in psychopharmacological Investigations - a review","volume":"71","author":"Parrott","year":"1980","journal-title":"Psychopharmacology"},{"issue":"7-8","key":"10.1002\/14651858.CD010631.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1345\/aph.1M721","article-title":"Lurasidone: an atypical antipsychotic for schizophrenia","volume":"46","author":"Risbood","year":"2012","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-244X-6-3","article-title":"The effect of verbalization strategy on wisconsin card sorting test performance in schizophrenic patients receiving classical or atypical antipsychotics","volume":"6","author":"Rossi","year":"2006","journal-title":"BMC Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010631.pub2-BIB0212|cit212","first-page":"655","article-title":"Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature","volume":"32","author":"Rzewuska","year":"1998","journal-title":"Psychiatria Polska"},{"issue":"5","key":"10.1002\/14651858.CD010631.pub2-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/875512251002600604","article-title":"Asenapine: a novel atypical antipsychotic agent for schizophrenia and bipolar I disorder","volume":"26","author":"Smith","year":"2010","journal-title":"Journal of Pharmacy Technology"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0216|cit216","unstructured":"Sterne JAC Egger M Moher D on behalf of the Cochrane Bias Methods Group Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/02813439308994842","article-title":"The G\u00f6teborg Quality of Life Instrument - a psychometric evaluation of assessments of symptoms and well-being among the women in a general population","volume":"11","author":"Sullivan","year":"1993","journal-title":"Scandinavian Journal of Primary Health Care"},{"issue":"2","key":"10.1002\/14651858.CD010631.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000026565","article-title":"Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia","volume":"39","author":"Takahashi","year":"1999","journal-title":"Neuropsychobiology"},{"issue":"11","key":"10.1002\/14651858.CD010631.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1097\/00004583-199511000-00013","article-title":"Emergence of transient compulsive symptoms during treatment with clothiapine","volume":"34","author":"Toren","year":"1995","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"s7","DOI":"10.1136\/bmj.39034.609074.94","article-title":"Chlorpromazine: unlocking psychosis","volume":"334 Suppl 1","author":"Turner","year":"2007","journal-title":"BMJ (Clinical research ed.)"},{"issue":"5","key":"10.1002\/14651858.CD010631.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0222|cit222","volume-title":"WHO model list of essential medicines","author":"World Health Organization","year":"March 2011"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0223|cit223","volume-title":"Wechsler Memory Scale - Fourth Edition (WMS-IV)","author":"Wechsler","year":"2009"},{"key":"10.1002\/14651858.CD010631.pub2-BIB0224|cit224","unstructured":"Wu T Li Y Liu G Bian Z Li J Zhang J Investigation of authenticity of 'claimed' randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. Proceedings of the 14th Cochrane Colloquium; 2006 October 23-26; Dublin Dublin 2006"},{"issue":"7","key":"10.1002\/14651858.CD010631.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD010631.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1192\/pb.24.4.130","article-title":"Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics","volume":"24","author":"Yorston","year":"2000","journal-title":"Psychiatric Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD010631.pub2-BIB0227|cit227","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s002130050834","article-title":"The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors","volume":"141","author":"Zhang","year":"1999","journal-title":"Psychopharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010631.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T05:13:31Z","timestamp":1748841211000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010631.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,5]]},"references-count":227,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010631.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,5]]}}}